(888) 391-1315



Our goal is to provide you the consumer with the latest news on prescription drugs and medical devices that have been linked to side effects, been recalled or been deemed unsafe.

Latest Actos Trial Begins With Expert Linking Drug to Bladder Cancer

Friday, January 23, 2015

The latest in a string of trials alleging the popular diabetes drug Actos caused users to develop bladder cancer started last week in Philadelphia, with stakes high for Japanese manufacturer Taketa Pharmaceutical.

The company faces more than 7,500 lawsuits in federal and state courts around the country from patients who developed the disease after taking Actos.

Read More

Doctors Paid $20 Million to Promote Xarelto and Other Blood Thinners

Thursday, January 15, 2015

With the market for newer anticoagulants growing to several billion dollars per year, it’s no surprise the leading competitors would spend a healthy chunk of change on advertising. Anyone with a TV has likely seen countless ads for Xarelto, Eliquis and Pradaxa.

What is somewhat unsettling, however, is that the manufacturers of these drugs also funnel millions of promotional dollars to doctors. Almost $20 million in just the past half year, to be exact.

Read More

Federal Judge Sets 33 New Yaz Lawsuits for Trial in 2015

Tuesday, January 13, 2015

With nearly $2 billion spent so far by German drug giant Bayer to settle Yaz blood clot lawsuits, it may come as a surprise that not one case has reached a jury decision. That could change this year as a new class of unresolved claims are being scheduled for trial.

In 2009, litigation got underway as a small number of lawsuits alleging Yaz blood clot injuries were consolidated to a dedicated federal court in Illinois. Since then, over 13,000 claims have been filed.

Read More

New Study From Israel Confirms Bleeding Risks of Xarelto

Monday, January 12, 2015

A study from Israeli doctors released last month added fuel to an ongoing debate over the safety of newer style oral blood thinner drugs, noting that medications like Xarelto and Pradaxa may carry greater risks for intestinal bleeding than standby option warfarin.

The comments are just the latest data in years of conflicting evidence from manufacturers and independent researchers. On one side, German companies Bohringer Ingelheim and Bayer have touted the clinical trials behind their drugs Pradaxa and Xarelto, saying the meds carry fewer risks than warfarin.

Read More

New UCLA Study Examines the Risk of Blood Thinners for Intra Cranial Hemorrhage

Wednesday, December 24, 2014

The American Medical Association’s official publication this week released a new study that adds further discussion to the safety of new-style anticoagulant drugs for those with atrial fibrillation. Specifically, it addressed whether they are more likely to cause intra-cranial hemorrhage.

For over 50 years, doctors prescribed warfarin for patients with atrial fibrillation to prevent blood clots and strokes. However, with severe diet restrictions and the requirement of regular blood testing, many sought an alternative.

Read More

FDA Issues Warning Over Antipsychotic Drug Geodon

Tuesday, December 16, 2014

The FDA issued a new warning last week for a popular antipsychotic drug used by millions of patients for bipolar disorder or schizophrenia after studies showed it may cause a deadly skin disease.

Geodon is the best-known version of the drug Ziprasidone, sold by Pfizer. It is also marketed under the brand names Zeldox and Zipwell by Actavis. It has been on the market since 2001 and is still prescribed to around 2.5 million people.

Read More

Xarelto Bleeding Cases Sent to Consolidated Court in Louisiana

Monday, December 15, 2014

A federal panel this week ruled that a growing number of claims over the blood thinner Xarelto will be sent to one central federal court for faster handling.

The Judicial Panel on Multidistrict Litigation, which consists of seven judges from around the country, decides whether lawsuits filed in different states have similar issues that could best be handled by one court. This prevents repetitious evidence gathering and conflicting judicial decisions.

Read More

Actos Maker Destroyed Evidence to Block Victims' Lawsuits, Jury Finds

Thursday, December 04, 2014

So far, around 8,000 patients in the United States have filed lawsuits against Japanese pharmaceutical giant Taketa alleging their blockbuster diabetes drug Actos caused them to develop bladder cancer.

Bloomberg reports eight of these cases have reached trial already, with five resulting in verdicts for the victims. In April, a jury awarded an astonishing $9 billion to a New York man afflicted with bladder cancer after Actos use.

Read More

Bayer Funds Study to Argue Against Yaz, Yasmin Blood Clot Risks

Wednesday, December 03, 2014

A new study released this year suggests that the birth control pills Yaz and Yasmin are just as safe, and no more likely to cause blood clots, as other types of oral contraceptives.

The only problem is, the study was funded by the company trying to sell the drugs, and is disputed by years of independent research.

Read More

Xarelto Among Fastest Growing Drugs Despite Rising Lawsuit Allegations

Monday, December 01, 2014

Since Bayer and Johnson & Johnson released their joint-effort blood thinning drug Xarelto on the public in 2011, they have seen overwhelming sales growth: the once-a-day blood clot preventative has taken over previous sales leader Pradaxa and completely outpaced rival Eliquis.

A report compiled last month by industry tracker FirstWord Pharma demonstrates just how much Xarelto has overtaken the anticoagulant market though. In the past 12 months, it has grown from $1.6 billion in yearly sales to a now staggering rate of $3.2 billion.

Read More

prev 1 2 3 4 next